At this year’s Lung Science Conference in Estoril, Portugal, researchers revealed that mesenchymal stem cells (MSCs) can be effective in treating chronic inflammatory lung diseases, such as COPD or cystic fibrosis, which currently have no cure. In pre-clinical trials, MSCs injected intravenously into mice with inflammatory lung diseases demonstrated an ability to repair the damaged lung tissue and alleviate inflammation by decreasing the number of neutrophils and monocytic cells, which are indicators of inflammation.
“These preliminary findings demonstrate the potential effectiveness of MSC treatment as a means of repairing the damage caused by chronic lung diseases such as COPD. The ability to counteract inflammation in the lungs by utilizing the combined anti-inflammatory and reparative properties of MSCs could potentially reduce the inflammatory response in individuals with chronic lung disease whilst also restoring lung function in these patients,” commented Dr. Declan Doherty, one of the professionals at the Conference.
This advancement in COPD and cystic fibrosis treatments demonstrates the best stem cells to use will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn how to bank your own valuable stem cells to insure your future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.